CME Group's (CME) global presence, compelling product portfolio, and focus on over-the-counter clearing services and effective capital deployment poise it well for growth.

What To Expect From CME Group Stock?

07:00am, Tuesday, 23'rd May 2023
CME Group's stock (NYSE: CME) has gained 8% YTD, as compared to the 9% rise in the S&P500 over the same period.
Here is how CME Group (CME) and Amerisafe (AMSF) have performed compared to their sector so far this year.
Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison.
A compelling and diversified product portfolio helps drive revenues of Zacks Securities and Exchanges industry players.
Chicago-based CME Group is my largest financial investment, thanks to its excellent business model, which comes with low capital requirements and a very high and sustainable dividend yield. The compan
CME Group (CME) Q1 results reflect higher revenues on increased trading volume.
CME Group (CME) came out with quarterly earnings of $2.42 per share, beating the Zacks Consensus Estimate of $2.36 per share. This compares to earnings of $2.11 per share a year ago.
CME Group's (CME) Q1 earnings are likely to have been aided by improved clearing, transaction fees and other revenues, and market data and information services.
While many finance-related stocks have come under pressure following banking concerns, all three of these have displayed relative strength.
CME Group (CME) stands to gain from market data distribution channels, higher custody fees and prudent capital deployment.
CME (CME) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The portfolio remains at record high levels of cash holdings, which is fine for the first time in a long time, cash is providing a decent return. Income growth is projected at 7.9% for the year, up fr

What Makes CME (CME) a New Buy Stock

01:44pm, Friday, 07'th Apr 2023
CME (CME) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
I'm reviewing my February and March results in this piece. My passive income stream grew by 22.63% in February and by 46.87% in March.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE